Lambda-Carrageenan - an overview | ScienceDirect Topics
Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding properties | PNAS
Antibodies | Free Full-Text | Antibody Fragments and Their Purification by Protein L Affinity Chromatography
Development of a novel affinity chromatography resin for platform purification of lambda fabs - Eifler - 2014 - Biotechnology Progress - Wiley Online Library
A generic cell surface ligand system for studying cell–cell recognition | PLOS Biology
Protein L - Wikipedia
Frontiers | Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs
Antibody Basics
Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses - ScienceDirect
The current role of clinical flow cytometry in the evaluation of mature B‐cell neoplasms - Seegmiller - 2019 - Cytometry Part B: Clinical Cytometry - Wiley Online Library
Covalently Engineered Protein Minibinders with Enhanced Neutralization Efficacy against Escaping SARS-CoV-2 Variants | Journal of the American Chemical Society
Interaction Analysis of the Spike Protein of Delta and Omicron Variants of SARS-CoV-2 with hACE2 and Eight Monoclonal Antibodies Using the Fragment Molecular Orbital Method | Journal of Chemical Information and Modeling
Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses | ACS Chemical Neuroscience
Case 966-- Clinical Chemistry Case
Regulation of protein secretion through chemical regulation of endoplasmic reticulum retention signal cleavage | Nature Communications
Cells | Free Full-Text | The Role of Protein Disorder in Nuclear Transport and in Its Subversion by Viruses
A PCP's Guide to Screening for Monoclonal Gammopathy of Undetermined Significance – Consult QD
How to Select Chromatography Media for the Purification of Antibodies
Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists